Dr. Vipul Sheth

About Dr. Vipul Sheth

Dr. Vipul Sheth is one of India's preeminent hemato-oncologists with a rich pool of experience spanning over 12 years, during which he undertook multiple procedures in bone marrow transplants, CAR T-cell therapy, T-cell engineering, and has other cellular therapies under his belt over and above pursuing a DM in Medical Oncology through Tata Memorial Hospital= Mumbai.
Worked as a senior physician for international experience at Hadassah Ein Kerem, Israel, in bone marrow transplants, and King's College Hospital in London, UK, in cellular therapy and CAR T-cell therapy for haematological malignancies..
He also pursued considerable post-doctoral research under distinguished mentors at the Fred Hutchinson Cancer Centre (Seattle, USA) and the University of Alabama, Birmingham, specialising in stem cell biology, genomics, T-cell therapy, and translational research.
Dr. Sheth also authored over 30 papers in top international journals, mostly Blood, Leukaemia, and Bone Marrow Transplant. He is also an energetic and active reviewer for many reputed journals and is part of several prestigious societies, such as EBMT and EHA.
He specialises in flow cytometry for MRD detection, genetic engineering, multi-omics, and bioinformatics. He aims to advance the bone marrow transplant and cellular therapy field in India as Senior Consultant and Head of Unit 3 in Haematology.

Conditions treated by Dr. Vipul Seth

Acute leukemia
Severe aplastic anaemia
Chronic leukemia
Bone marrow transplant- including half-matched transplant (haploidentical donor transplants)
Cellular therapy and T cell engineering

Area of Interest

Bone marrow transplant (BMT) and stem cell transplantation
CAR T-cell therapy and T-cell engineering
Cellular therapy for haematological malignancies (like leukaemia, lymphoma, aplastic anaemia)
Flow cytometry for minimal residual disease (MRD) detection in AML
Genetic engineering, multi-omics, bioinformatics, and translational research in T-cell biology and stem cell metabolism

Qualification

BBS: Grant Medical College, Mumbai, India (2005)
MD Medicine (2005-2008)

Work Experiences

Clinical Instructor (Assistant Professor) – Prince Aly Khan Hospital, Mumbai, India (2014 – 2015)
Assistant Professor, Tata Memorial Hospital, Mumbai, India (2017 – 2018)
Senior physician in Bone marrow transplant- Hadassah Ein Kerem, Jerusalem, Israel Senior physician in haematology (myeloid disorders/AA)/cellular therapy Kings College Hospital, London, UK (2015 – 2019)
Post doc fellowship/clinical attending- program in immunology- clinical research division- Fred Hutchinson Cancer Research center, USA (2019-2024)

Global Team of Board Certified Surgeons and Medical Specialists
Written Second Opinion report delivered within 5 days
Option to avail the Video Consultation with the Lead Doctor of the board

Access Our most trusted Medical Second Opinion

Telemedicine Doctors

Do you know?

You can book a video consultation with Dr. Vipul Sheth on our platform

Consult Online

CERTIFICATIONS (7)

Fellowship in training haematology, CMC Vellore, India / Tata Memorial Hospital, Mumbai, India (2010 – 2014)
Fellowship (DM), Haemato-oncology Bone marrow transplant and solid tumours, Tata Memorial Hospital, Mumbai, India
2008 India- active, Israel (2015- inactive), UK- 2017 active
Board Certification or Eligibility (equivalent): 2014
Homi Bhabha institute of science, Mumbai, India
Diploma in clinical trials, London School of Tropical Hygiene
Board certification USMLE step 1 and step 2- USA national board exams

MEMBERSHIPS (6)

ASH membership from May 2021 onwards
EBMT membership-sponsored (Prof Mohamd Mohty) in process
EHA guest, June 2020 onwards
IACH membership June 2020- present
Active member of ALWP/CMWP/CITWP/SAA WP party of EBMT
IOSI- Immuno-oncology society of India- June 2020 till present

RESEARCH PAPERS AND PUBLICATIONS (12)

Anderson NR, Sheth V, Li H, Harris MW, Qiu S, Crossman DK, et al. Microenvironmental CXCL12 deletion enhances Flt3-ITD acute myeloid leukemia stem cell response to therapy by reducing p38 MAPK signaling. Leukemia. 2023;37(3):560-70.
Sheth V, Qui S et al, Metabolic adaptation of leukemic stem cells to TKI- accepted for publication Blood- 2023
Raj K, Eikema DJ, Sheth V, Koster L, de Wreede LC, Blaise D, et al. Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT. Blood Cancer J. 2022;12(9):140.
Sheth V…. Mclornan D, Raj K, et al. Pre-emptive DLI- Long-term outcomes of patients with mixed chimerism in acute Leukaemia- Blood cancer journal- June 2021
Sheth VS, Gauthier J. Taming the beast: CRS and ICANS after CAR T-cell therapy Bone Marrow Transplant. 2020.
Sheth V, Volt F, Sanz J, Clement L, Cornelissen J, Blaise D, et al. Reduced-Intensity versus Myeloablative Conditioning in Cord Blood Transplantation for Acute Myeloid Leukemia (40-60 years) across Highly Mismatched HLA Barriers-On Behalf of Eurocord and the Cellular Therapy & Immunobiology Working Party (CTIWP) of EBMT. Biol Blood Marrow Transplant. 2020;26(11):2098-104.
Biernacki MA, Sheth VS, Bleakley M. T cell optimization for graft-versus-leukemia responses. JCI Insight. 2020;5(9).
Summers C, Sheth VS, Bleakley M. Minor Histocompatibility Antigen-Specific T Cells. Front Pediatr. 2020; 8:284.
Sheth VS, Potter V, Gandhi SA, Kulasekararaj AG, de Lavallade H, Muus P, et al. Similar outcomes of alemtuzumab-based hematopoietic cell transplantation for SAA patients older or younger than 50 years. Blood Adv. 2019;3(20):3070-9.
Sheth V, Kennedy V, de Lavallade H, McLornan D, Potter V, Engelhardt BG, et al. Differential Interaction of Peripheral Blood Lymphocyte Counts (ALC) With Different in vivo Depletion Strategies in Predicting Outcomes of Allogeneic Transplant: An International 2 Center Experience. Front Oncol. 2019; 9:623.
Sheth V, Labopin M, Canaani J, Volin L, Brecht A, Ganser A, et al. Comparison of FLAMSA-based reduced intensity conditioning with treosulfan/fludarabine conditioning for patients with acute myeloid leukemia: an ALWP/EBMT analysis. Bone Marrow Transplant. 2019;54(4):531-9.
Sheth V, Nachmias B, Grisariu S, Avni B, Or R, Shapira M. Augmented myeloablative conditioning with thiotepa in acute myeloid leukemia – improved outcomes with similar toxicity. Leuk Lymphoma. 2019;60(3):726-33.

Share Your Experience about Dr. Vipul Sheth

Write Your Review

PROCEDURES

CAR-T
Castleman Disease Treatment

FREQUENTLY ASKED QUESTIONS

Is Doctor Vipul Seth doing teleconsultation on the MediGence platform?

Dr. Vipul Seth can teleconsult on the MediGence platform.

How long is the consultation?

The consultation can last from 15 to 30 minutes. Depending on the patient’s queries and the doctor's medical suggestions, it may exceed the estimated time.

How soon can the consultation be organised?

We have Medical specialists and board-certified doctors on our panel of doctors. The consultation will be organised within 24 to 48 hours or based on the availability of the doctor and the patient.

Is a follow-up consultation included in the consultation price?

No, the follow-up consultation fee is not included in the consultation price. The patient will be required to re-book the consultation.

How do I share my medical record with the doctor for review?

The option to share your medical records is available between the steps of the form provided to you on the website.

Can I book my procedure with the doctor post-consultation?

Yes. If you are satisfied with the consultation, you can go ahead with treatment packages for your diagnosis with the help of our case managers.

Can we get an estimate for the procedure?

Yes. Our case manager will provide the cost estimate, the doctor’s opinion, and crucial information about travelling to your medical destination.

FAQ's Related to Hematologist

What conditions does a hematologist treat?

A haematologist treats blood disorders such as anaemia, leukaemia, lymphoma, clotting disorders, haemophilia, myeloma, and platelet abnormalities. They also manage bone marrow disorders and blood cancers.

When should I see a hematologist?

You should consult a haematologist if you have abnormal blood counts, frequent bruising, prolonged bleeding, unexplained fatigue, recurrent infections, or if you have been diagnosed with a blood-related disorder.

What tests might a hematologist recommend?

Standard tests include complete blood count (CBC), bone marrow biopsy, coagulation tests, flow cytometry, genetic tests, and advanced imaging studies to assess blood and marrow health.

What is the role of a hematologist in cancer care?

Haematologists manage blood cancers like leukaemia, lymphoma, and myeloma. They guide chemotherapy, bone marrow/stem cell transplantation, immunotherapy (like CAR T-cell therapy), and supportive treatments.

How is blood cancer diagnosed?

Blood cancers are diagnosed through blood tests, bone marrow biopsy, genetic testing, imaging scans, and sometimes molecular or cytogenetic studies to find specific mutations.

What is bone marrow transplantation?

Bone marrow transplant (or stem cell transplant) replaces damaged or destroyed bone marrow with healthy stem cells. It is often used to treat leukaemia, lymphoma, myeloma, and severe blood disorders.

Welcome To MediGence

Your Notifications

2+

2